New cocktail of drugs and radiation takes on tough lung cancer

NCT ID NCT05386888

Completed Disease control Sponsor: Genfleet Therapeutics (Shanghai) Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tested whether adding two newer drugs—GFH018 and toripalimab—to standard chemoradiotherapy could help people with stage III non-small cell lung cancer that cannot be surgically removed. The study enrolled 65 adults and measured how many patients saw their tumors shrink or disappear. The goal is to find a more effective way to control this advanced cancer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: GFH018 (a targeted drug) and toripalimab (an immunotherapy) combined with chemotherapy (paclitaxel, carboplatin, cisplatin, or pemetrexed) and radiation therapy
What this could lead to: If successful, this combination could offer a new treatment option to shrink or control advanced lung cancer that cannot be removed by surgery.
What could go wrong: This is an early phase 2 trial with only 65 participants, so results may not apply to everyone. Adding multiple drugs and radiation raises the risk of serious side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NSCLC, STAGE III are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NSCLC, STAGE III

Contacts and locations

Locations

West China Hospital, Sichuan University

Chengdu, Sichuan, 610000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.